tetracyclines

Recent Rosacea Blog Posts

Some very preliminary internet crumbs about a new possible rosacea treatment under development. The treatment under development is listed as a “novel tetracycline”. Warner Chilcott Limited calls itself a “specialty pharmaceutical company, that engages in the development, manufacture, marketing, and sale of branded prescription pharmaceutical products in women’s healthcare and dermatology segments primarily in the […]

Continue Reading

A recent investor presentation from Collagenex shows some interesting insights into how Collagenex are promoting Oracea. Oracea is promoted as safe and effective for long term use. It was reported that the average duration of Oracea therapy is 4 months, compared to an average of 2.5 months for other rosacea prescriptions. 52% of Oracea prescriptions […]

Continue Reading

Despite promising looking Phase 1 and initial Phase 2 dose finding studies, Incyclinide will no longer be developed as a treatment for rosacea. Incyclinide is a chemically modified tetracycline that its developers – Collagenex, was hoping would become another systemic treatment for rosacea. We did get a warning in May that clinical trials for Incyclinide […]

Continue Reading

Collagenex has announced that their ongoing trials to find the best dosage for Incyclinide have discovered that 40mg can cause photo-toxicity. Collagenex is conducting parallel Phase II trials for Incyclinide for both acne and rosacea. As detailed in a recent news item, incyclinide targets conditions other than rosacea, Incyclinide differs from a non-antibiotic tetracycline in […]

Continue Reading

There has been a lot of publicity lately about Oracea, which is a low dosage, sustained release 40mg form of doxycyline. Oracea was born out of the expiration of the patent on periostat – a twice a day  20mg dose of doxycycline originally targetted at gum disease. Another new low dose antiobiotic is Solodyn (45mg, 90mg […]

Continue Reading

 

Top

Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.